OBESITY DRUGS HAVE ANOTHER SUPERPOWER: TAMING INFLAMMATION

Summary from the TLDR newsletter

The drugs classified as GLP-1 receptor agonists have been shown to reduce inflammation in the liver, kidneys, heart, and brain. These drugs include semaglutide and tirzepatide, which are marketed as treatments for diabetes and obesity. This effect is leading scientists to hope that they could be used to treat Parkinson's and Alzheimer's diseases, which both involve brain inflammation. More than 20 clinical trials are now exploring the drugs as therapies for the two conditions.